Join us at the Parker Hotel in Palm Springs, California, to meet colleagues, share ideas, and make new connections in the pursuit of therapeutics for Huntington's disease.
ViewOver the course of four stimulating days of in-depth discussions in 20 different conferences, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy and Analytics, Sensors and Wearables, Artificial Intelligence, Clinical Biomarker Strategy, Precision Medicine, Clinical Biomarkers, and an all new track on Medical Device Clinical Trial Operations and Regulations.
The show is brought to you by the team at Shares Magazine, in partnership with Cenkos Securities. The Growth and Innovation Forum connects top experts, who will share their in-depth knowledge of investing and meet directors from fast-growing and technology led London listed companies.
For 5 years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science business strategy, investment, partnering, deal making and commercialisation.
LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life science giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.
The industry’s c-suite will be joined by the sector’s most active investors, pharma and healthtech BD&L teams, key stakeholders and top tier service companies who are moving the sector forward.
HAI 2020 will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily spring from brief presentations by active investigators who will report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
ViewThe program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover, there are panels on innovation in NeuroTech covering banking, device, diagnostics and software. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma, biotech and medtech companies.
The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
ViewThis year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe. Our event will again feature leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors.
The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
137-144 of 162 results